Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.
|Study Design:||Observational Model: Defined Population
Time Perspective: Longitudinal
|Official Title:||Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00396110
|Study Chair:||Ingrid van Geel, MD||AstraZeneca|
|Study Chair:||Ingeborg Vosjan, MD||AstraZeneca|